Influence of obesity in critical illness patients at Serum Levels of vancomycin with continuous applicatio

• Conditions: A41; E66; Other sepsis; Obesity

• Registration Number: DRKS00011176
• Lead Sponsor: niversitätsklinikum Leipzig

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-27
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1700

Inclusion Criteria

treatment at ICU with infection (clinical suspected or with microbiological cultures)
continuous application of vancomycin
Age not less than 18
between 2009 and 2016

Exclusion Criteria

BMI < 18.5 kg/m2

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
number of treatment days with serum level below the minimum of target of vancomycin (serum level <20mg/L)

Secondary Outcome Measures

Name	Time	Method
incidence of Dosis changing<br>Duration until reaching the target levels<br>incidence of overdosing<br>mortality at day 28,90, at discharge from intensive care unit and hospital<br>SAPS II (simplified acute physiology) and SOFA-score (sequential organ failure assessment)<br>incidence of acute kidney injury<br>days without renal replacement therapy<br>Ventilator free days